A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

BACKGROUND: Polycythemia vera (PV) is a myeloproliferative neoplasm associated with somatic gain-of-function mutations of Janus kinase-2 (JAK2). Therapeutic options are limited in patients with advanced disease. Ruxolitinib, an oral JAK1/JAK2 inhibitor, is active in preclinical models of PV. The lon...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstovsek, Srdan, Passamonti, Francesco, Rambaldi, Alessandro, Barosi, Giovanni, Rosen, Peter J, Rumi, Elisa, Gattoni, Elisabetta, Pieri, Lisa, Guglielmelli, Paola, Elena, Chiara, He, Shui, Contel, Nancy, Mookerjee, Bijoyesh, Sandor, Victor, Cazzola, Mario, Kantarjian, Hagop M, Barbui, Tiziano, Vannucchi, Alessandro M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231215/
https://www.ncbi.nlm.nih.gov/pubmed/24258498
http://dx.doi.org/10.1002/cncr.28441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231215/
https://www.ncbi.nlm.nih.gov/pubmed/24258498
http://dx.doi.org/10.1002/cncr.28441

Ejemplares similares